|
 Aug 21, 2007 Sensigen Selected as Featured Company at Mac Conference Ann Arbor, MI and Philadelphia, PA ---SensiGen LLC, a biotechnology company focused on developing proprietary gene-based molecular diagnostics announced today that it has been selected as one of only 12 life sciences companies to be featured presenters at the upcoming Mid-Atlantic Capital (MAC) Conference at the Philadelphia Marriott Downtown on October 23 and 24, 2007. The MAC Conference, a production of the Mid-Atlantic Capital Alliance, is the premier capital investor gathering in the Mid-Atlantic region, offering unparalleled speakers, panels, presentations, networking, and visibility opportunities to its sponsors and participating entrepreneurs. Typically, more than 1,100 people attend this annual event, including 250 private equity professionals and venture capital investors from across the Mid-Atlantic region. SensiGen is one of only a handful of companies selected from a large pool of applicants to be invited as a "Featured Company" to present at the conference. "We are honored and extremely grateful to be invited to present at this exclusive venue," said Shawn M. Marcell, President and CEO of SensiGen. "The MAC Conference is one of the longest running, most respected, and best attended venture conferences in the U.S. and is another example of the outstanding resources available to start-up companies in the Mid-Atlantic region." The Mid-Atlantic Capital Alliance is the catalyst organization promoting the Greater Philadelphia region as one of North America's top private equity markets from venture to buyout. For further information about the MAC Conference and the Mid-Atlantic Capital Alliance please visit, http://www.macalliance.com. About SensiGen, LLC: SensiGen is a development stage biotechnology company focused on gene-based molecular diagnostics. The Company's develops and commercializes advanced molecular diagnostic tests for early detection of diseases, improving standards of care and reducing overall health costs. Current products in development include gene-based tests for human papillomavirus (HPV), the primary cause of cervical cancer, nephrin for chronic kidney disease (CKD), Crohn's and colitis, lupus and others. SensiGen's proprietary molecular diagnostic assays offer dramatic improvements over current methods, and can potentially provide significant value to patients, care givers, and insurers.
|
|
